SummitTX Capital’s Apellis Pharmaceuticals APLS Stock Holding History

SummitTX Capital’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-20,351	Closed	-$819K	–	776
2026 Q1	$819K	Buy	+20,351	New	+$439K	0.03%	487
2025 Q4	–	Sell	-17,232	Closed	-$390K	–	694
2025 Q3	$390K	Buy	+17,232	New	+$402K	0.02%	576

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

SummitTX Capital's APLS Position: Q2 2026 in Review

SummitTX Capital sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 20,351 shares — an estimated $819K sold.

SummitTX Capital first reported a position in APLS in Q3 2025 and held it in 2 quarters. The position peaked at $819K in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

SummitTX Capital reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
SummitTX Capital sold 20,351 Apellis Pharmaceuticals shares in Q2 2026, an estimated $819K.
SummitTX Capital first reported a position in Apellis Pharmaceuticals in Q3 2025 and held it in 2 quarters.
SummitTX Capital's Apellis Pharmaceuticals position peaked at $819K in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.